March 16, 2020 / 12:08 PM / in 19 days

BRIEF-Zai Lab Announces Acceptance Of SNDA Submission Of Zejula For First-Line Maintenance Treatment Of Ovarian Cancer In China By The NMPA

March 16 (Reuters) - Zai Lab Ltd:

* ZAI LAB ANNOUNCES ACCEPTANCE OF SNDA SUBMISSION OF ZEJULA® (NIRAPARIB) FOR FIRST-LINE MAINTENANCE TREATMENT OF OVARIAN CANCER IN CHINA BY THE NMPA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below